Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer—Does pT0 Predict Better Survival than pTa/Tis/T1?

Journal of Urology

Volumn 195, Issue 4, 2016, Pages 886-893

  Zargar, Homayoun ^a   Zargar Shoshtari, Kamran ^b   Lotan, Yair ^c   Shah, Jay B ^d   van Rhijn, Bas W ^e   Daneshmand, Siamak ^f   Spiess, Philippe E ^b   Black, Peter ^a   Fairey, Adrian S ^g   Mertens, Laura S ^g   Horenblas, Simon ^g   Dinney, Colin P ^g   Mir, Maria C ^g   Ercole, Cesar E ^g   Stephenson, Andrew J ^g   Krabbe, Laura Maria ^g   Cookson, Michael S ^g   Jacobsen, Niels Erik ^g   Barocas, Daniel A ^g   Griffin, Joshua ^g   Holzbeierlein, Jeff M ^g   Montgomery, Jeffrey S ^g   Morgan, Todd M ^g   Vasdev, Nikhil ^g   Thorpe, Andrew C ^g   Aning, Jonathan ^g   Yu, Evan Y ^g   Wright, Jonathan L ^g   Xylinas, Evanguelos ^g   Campain, Nicholas J ^g   Pourmalek, Farshad ^g   McGrath, John S ^g   Kassouf, Wassim ^g   Dall'Era, Marc A ^g   Seah, Jo An ^g   Sridhar, Srikala S ^g   Sharma, Pranav ^g   Shariat, Shahrokh F ^g   North, Scott ^g   Grivas, Petros ^g   Gandhi, Nilay ^g   Bivalacqua, Trinity J ^g   more..

^a VANCOUVER PROSTATE CENTRE   (Canada)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g NONE

Author keywords

cystectomy; drug therapy; neoadjuvant therapy; urinary bladder neoplasms

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; TAXANE DERIVATIVE; VINBLASTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYSTECTOMY; FEMALE; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE INVASIVE BLADDER CANCER; NEOADJUVANT CHEMOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; BLADDER TUMOR; COMPARATIVE STUDY; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES; PROGNOSIS; SURVIVAL RATE;

AGED; ANTINEOPLASTIC AGENTS; CYSTECTOMY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 84966293706     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2015.10.133     Document Type: Article

References (11)

1. Witjes, J.A., Comperat, E., Cowan, N.C., et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol, 65, 2014, 778.
2. NCCN Guidelines for Bladder Cancer Version 1.2015. Available at https://www.nccn.org/.
3. Grossman, H.B., Natale, R.B., Tangen, C.M., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med, 349, 2003, 859.
4. Petrelli, F., Coinu, A., Cabiddu, M., et al. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. Eur Urol, 65, 2014, 350.
5. Van Allen, E.M., Mouw, K.W., Kim, P., et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov, 4, 2014, 1140.
6. Groenendijk, F.H., de Jong, J., Fransen van de Putte, E.E., et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol, 2015 Epub ahead of print.
7. Zargar, H., Espiritu, P.N., Fairey, A.S., et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol, 67, 2015, 241.
8. Scattoni, V., Da Pozzo, L., Nava, L., et al. Five-year results of neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy plus radical cystectomy in locally advanced bladder cancer. Eur Urol, 28, 1995, 102.
9. Sonpavde, G., Goldman, B.H., Speights, V.O., et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer, 115, 2009, 4104.
10. Dinney, C.P., Hansel, D., McConkey, D., et al. Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. Urol Oncol, 32, 2014, 1108.
11. Powles, T., Eder, J.P., Fine, G.D., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature, 515, 2014, 558.